Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza
Interventions: Fluzone® (IM), Fluzone® Intradermal (ID), 2011-2012 FluMist®; Biological
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 34 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Respiratory Tract Infections, Covid19, Flu Like Illness
Interventions: Vitamin D supplementation; Dietary Supplement
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 877 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Influenza
Interventions: Seasonal Influenza DNA vaccine, TIV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 316 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Stanford, California • Iowa City, Iowa • St Louis, Missouri + 1 more

Conditions: Influenza
Interventions: Oseltamivir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Up to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 7
States / cities: Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 4 more

Conditions: Influenza A, Influenza B
Interventions: Intravenous hyperimmune immunoglobulin (IVIG), Placebo for IVIG; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 17
States / cities: San Diego, California • Denver, Colorado • Chicago, Illinois + 14 more

Conditions: Reminder Systems, Influenza Vaccines
Interventions: Reminders; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Months to 17 Years
Enrollment: 25,531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Influenza
Interventions: 2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine; Biological
Lead sponsor: Kaiser Permanente; Other
Eligibility: 5 Years to 8 Years
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Influenza, COVID-19
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Flucelvax(R), Human Challenge virus; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza, Human
Interventions: Flu shot text messages; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 74,811 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Danville, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Influenza, Respiratory Tract Infections
Interventions: Text Fixed R/R Messages with Direct Appointment Schedule Link, Text Pre-Appointment Reminder, Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link, Portal Fixed R/R Messages with Direct Appointment Schedule Link, Portal Pre-Appointment Reminder; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 6 Months and older
Enrollment: 262,085 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Influenza
Interventions: MK-1406, Placebo; Combination Product
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 12 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 135
States / cities: Anniston, Alabama • Cullman, Alabama • Glendale, Arizona + 116 more

Conditions: Not Condition-specific
Interventions: In-app and push notification mobile messages; Behavioral
Lead sponsor: Evidation Health; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50,286 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Influenza, Fever
Interventions: Mammalian cell based flu vaccine, Egg based flu vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 2,055 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 18
States / cities: Mobile, Alabama • Ponte Vedra, Florida • Augusta, Kansas + 12 more

Conditions: Influenza
Interventions: Influenza virus vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza
Interventions: Influenza VLP Vaccine, TIV; Biological
Lead sponsor: Novavax; Industry
Eligibility: 60 Years and older
Enrollment: 467 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Pembroke Pines, Florida • Rochester, Minnesota • Providence, Rhode Island + 3 more

Conditions: Influenza
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Influenza
Interventions: mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine, mRNA-1345, mRNA-1045; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza
Interventions: Flucelvax® (ccIIV3), Flublok® (RIV3); Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 606 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Phoenix, Arizona • Tempe, Arizona • Atlanta, Georgia + 3 more

Conditions: Asthma in Children, Vaccine Adverse Reaction, Vaccine Reaction, Asthma, Wheezing, Influenza
Interventions: Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine (IIV); Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 5 Years to 11 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Durham, North Carolina • Cincinnati, Ohio • Nashville, Tennessee

Conditions: Birth Outcomes, Safety, Adverse Event Following Immunization
Interventions: mRNA COVID-19 vaccine, IIV4 (quadrivalent inactivated influenza vaccine); Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 6
States / cities: Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 2 more

Conditions: Influenza
Interventions: Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 753 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: SARS-CoV-2, Influenza
Interventions: mRNA-1073, mRNA-1010, mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 14
States / cities: Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more

Conditions: Avian Influenza, Bird Flu
Interventions: ND1.1, Placebo control; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

Vitamin D3 Supplementation to Prevent Respiratory Tract Infections

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates_2nd Trial in Colorado

A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age

Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination

Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates

Patient Portal Flu Vaccine Reminders (5)

A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)

Promoting Flu Vaccination Through a Mobile Wellness Program

Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults

Influenza IMPRINT Cohort: Defining the Impact of Initial Influenza Exposure on Immunity in Infants

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

Immunogenicity of Influenza Vaccinations

Safety of LAIV4 in Children With Asthma

Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

Safety Study of an Oral Vaccine to Prevent Avian Influenza